search
Back to results

Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)

Primary Purpose

Pulmonary Disease, Chronic Obstructive

Status
Terminated
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Combivent® HFA inhalation aerosol
Combivent® CFC inhalation aerosol
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female patients 40 years of age or older
  2. A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
  3. A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
  4. Able to perform technical satisfactory pulmonary function test
  5. Able to be trained in the proper use of a MDI
  6. Having signed an informed consent from prior to participation in the trial
  7. Affiliation to the French social security system or beneficiary of such a system

Exclusion Criteria:

  1. Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
  2. Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
  3. Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
  4. Serum potassium level above or below the normal range
  5. Total blood eosinophil count >=600/mm³
  6. Recent history (i.e., one year or less) of myocardial infarction
  7. Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
  8. History of cancer, other than treated basal cell carcinoma, within the last five years
  9. History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
  10. History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
  11. History of asthma, allergic rhinitis or atopy
  12. History of or active alcohol or drug abuse
  13. Known active tuberculosis
  14. Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
  15. Known symptomatic prostatic hypertrophy or bladder neck obstruction
  16. Known narrow-angle glaucoma
  17. Current significant psychiatric disorders
  18. Regular use of daytime oxygen therapy
  19. Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
  20. Use of cromolyn sodium or nedocromil sodium
  21. Use of antihistamines.
  22. Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
  23. Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
  24. Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
  25. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
  26. Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations
  27. Use of an investigational drug within one month or six half lives prior to the screening visit
  28. Previous participation in this study
  29. Patient deprived of their freedom by a judicial or administrative decision
  30. Patient leaving in medical or social establishments
  31. Patient hospitalized for mental disorder without his (her) consent
  32. Patient under guardianship
  33. Patient in emergency situations

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Combivent® HFA

    Combivent® CFC

    Arm Description

    Outcomes

    Primary Outcome Measures

    Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
    Number of patients with clinically significant changes in vital signs (blood pressure, puls rate, respiratory rate)
    Changes in intra ocular pressure (IOP)
    Changes in serum potassium levels
    Changes in serum glucose levels
    Number of patients with clinically significant changes from baseline in clinical laboratory evaluations
    Number of patients with adverse events including paradoxical bronchospasm
    Number of patients with clinically significant changes from baseline in physical examination

    Secondary Outcome Measures

    Change in FEV1 (forced expiratory volume in one second)
    Change in FVC (forced vital capacity)

    Full Information

    First Posted
    July 4, 2014
    Last Updated
    August 29, 2018
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02182869
    Brief Title
    Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
    Official Title
    Safety Assessment of Cumulative Dose of Combivent® HFA-propelled Metered Dose Inhaler in Comparison to Combivent® CFC-propelled Metered Dose Inhaler. A Randomised, Double-blind, Active-controlled, Two-way Cross-over Study in COPD Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Terminated
    Study Start Date
    April 2001 (undefined)
    Primary Completion Date
    August 2001 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with COPD.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pulmonary Disease, Chronic Obstructive

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Crossover Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    7 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Combivent® HFA
    Arm Type
    Experimental
    Arm Title
    Combivent® CFC
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Combivent® HFA inhalation aerosol
    Intervention Type
    Drug
    Intervention Name(s)
    Combivent® CFC inhalation aerosol
    Primary Outcome Measure Information:
    Title
    Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
    Time Frame
    Baseline, up to 8 days after last treatment day
    Title
    Number of patients with clinically significant changes in vital signs (blood pressure, puls rate, respiratory rate)
    Time Frame
    Baseline, up to 8 days after last treatment day
    Title
    Changes in intra ocular pressure (IOP)
    Time Frame
    Baseline, up to 30 min after last drug administration
    Title
    Changes in serum potassium levels
    Time Frame
    Baseline, up to 180 min after last drug administration
    Title
    Changes in serum glucose levels
    Time Frame
    Baseline, up to 60 min after last drug administration
    Title
    Number of patients with clinically significant changes from baseline in clinical laboratory evaluations
    Time Frame
    Baseline, 8 days after last treatment day
    Title
    Number of patients with adverse events including paradoxical bronchospasm
    Time Frame
    Up to 8 days after last treatment day
    Title
    Number of patients with clinically significant changes from baseline in physical examination
    Time Frame
    Baseline, 8 days after last treatment day
    Secondary Outcome Measure Information:
    Title
    Change in FEV1 (forced expiratory volume in one second)
    Time Frame
    Baseline, up to 180 min after last drug administration
    Title
    Change in FVC (forced vital capacity)
    Time Frame
    Baseline, up to 180 min after last drug administration

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female patients 40 years of age or older A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%. A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year Able to perform technical satisfactory pulmonary function test Able to be trained in the proper use of a MDI Having signed an informed consent from prior to participation in the trial Affiliation to the French social security system or beneficiary of such a system Exclusion Criteria: Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL Serum potassium level above or below the normal range Total blood eosinophil count >=600/mm³ Recent history (i.e., one year or less) of myocardial infarction Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy History of cancer, other than treated basal cell carcinoma, within the last five years History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1 History of asthma, allergic rhinitis or atopy History of or active alcohol or drug abuse Known active tuberculosis Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2 Known symptomatic prostatic hypertrophy or bladder neck obstruction Known narrow-angle glaucoma Current significant psychiatric disorders Regular use of daytime oxygen therapy Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants Use of cromolyn sodium or nedocromil sodium Use of antihistamines. Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2 Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations Use of an investigational drug within one month or six half lives prior to the screening visit Previous participation in this study Patient deprived of their freedom by a judicial or administrative decision Patient leaving in medical or social establishments Patient hospitalized for mental disorder without his (her) consent Patient under guardianship Patient in emergency situations

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1012/1012.43_U03-1212.pdf
    Description
    Related Info

    Learn more about this trial

    Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)

    We'll reach out to this number within 24 hrs